- /
- Supported exchanges
- / US
- / GRAL.NASDAQ
GRAIL, LLC (GRAL NASDAQ) stock market data APIs
GRAIL, LLC Financial Data Overview
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GRAIL, LLC (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GRAIL, LLC data using free add-ons & libraries
Get GRAIL, LLC Fundamental Data
GRAIL, LLC Fundamental data includes:
- Net Revenue: 147 M
- EBITDA: -377 852 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-19
- EPS/Forecast: -2.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRAIL, LLC News
New
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Wall Street expects a year-over-year increase in earnings on higher revenues when Ultragenyx (RARE) reports results for the quarter ended March 2026. While this widely-known consensus outlook is impor...
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL, Inc. GRAL recently announced a strategic collaboration with Epic to integrate its Galleri multi-cancer early detection (MCED) test into one of the most widely used electronic health record (EHR...
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GRAIL, Inc. (�...
Better Healthcare Stock to Own in a Recession: Defensive or Growth?
The ongoing conflict in Iran is creating a risk that the economy could fall into a recession. Inflationary pressures from soaring energy and food prices stemming from the inability to transport crude ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.